TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease. (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025)